CD47 and neoplasm: Another anti-CD47-based BsAb, N1801 (TG Therapeutics, Inc.)was designed to target CD47 and mesothelin (MSLN), an antigen overexpressed in multiple solid tumors, and was demonstrated to efficiently kill MSLN+ tumor cells without generating an adverse hematological profile in a nonhuman primate study (AACR Annual Meeting 2019).173,174 The synergistic activation of innate and adaptive immune responses is also promising for tumor immunotherapy because it leads to the modulated activity of two highly potent effector cells, NK cells, and T cells.